COLL COLLEGIUM PHARMACEUTICAL, INC — earnings, filings & institutional moves

Price chart

Daily historical data with per-account defaults

Latest close

$35.85

Period return

-11.25 (-23.89%)

Volume

301.6K

2026-07-21O $35.26 H $36.29 L $35.15 C $35.85MA5 $36.09MA20 $35.89MA60 $34.68MA120 $36.78

6M · 124 barsYahoo Finance · USD2026-01-22 → 2026-07-21

Recent event timeline

Filings, earnings, research, and institutional changes — newest first

View all →

2026. 08. 06.Highin 16 days
다음 실적 발표 예정
예정된 실적 발표입니다. 일정과 시장 기대치를 확인하세요.
2026. 05. 15.High2 months ago
13F 기관 보유 변화 — TWO SIGMA INVESTMENTS, LP
신규 편입 · 포트폴리오 비중 0.02%
2026. 03. 20.LowBUY4 months ago
HC Wainwright & Co.: Buy
US analyst rating / recommendation change.
2026. 03. 19.LowBUY4 months ago
Needham: Buy
US analyst rating / recommendation change.
2026. 02. 27.LowBUY5 months ago
Needham: Buy
US analyst rating / recommendation change.
2026. 01. 09.LowBUY6 months ago
Barclays: Overweight
US analyst rating / recommendation change.
2026. 01. 09.LowBUY6 months ago
HC Wainwright & Co.: Buy
US analyst rating / recommendation change.
2026. 01. 08.LowBUY6 months ago
Needham: Buy
US analyst rating / recommendation change.
2025. 12. 10.MediumBUY7 months ago
Barclays: Overweight
US analyst rating / recommendation change.
2025. 11. 08.LowBUY9 months ago
Truist Securities: Buy
US analyst rating / recommendation change.

Recent earnings

Consensus vs. actual, and revenue trend

Earnings tab →

Research actions

Consensus PT $54.33 · 6 analysts

Research tab →

AI Brief (Premium)

Automated summary from public sources · not investment advice

Brief tab →

No AI brief generated yet. You can create one from the Brief tab.

Top institutions (13F)

Ranked by position value

Institutions tab →

Company info

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. The company's portfolio includes Jornay PM, a central nervous system stimulant prescription medicine that contains methylphenidate HCl for the treatment of attention deficit hyperactivity disorder; Belbuca, a buccal film that contains buprenorphine for severe and persistent pain that requires an extended treatment period; Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone for the management of pain severe enough to require daily; Nucynta ER and Nucynta IR, which are extended-release and immediate-release oral formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. Collegium Pharmaceutical, Inc. was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. The company was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
HQ: Stoughton, MA, United States
Fiscal year end

Quarter	Date	Time	EPS est.	EPS actual	Surprise	Rev. est.	Rev. actual	Status
—	2026. 08. 06.	After market close (AMC)	$1.75	—	—	$203.48M	—	Scheduled
FY2026 Q1	2025. 03. 31.	Time TBD	—	$0.07	—	—	$177.76M	Reported
FY2025 Q3	2024. 09. 30.	Time TBD	—	$1.51	—	—	$449.5M	Reported
FY2025 Q2	2024. 06. 30.	Time TBD	—	$1.24	—	—	$290.2M	Reported

#	Institution	Mandate	Shares	Value	Weight	Change	Position
1	TWO SIGMA INVESTMENTS, LP	TWO SIGMA INVESTMENTS, LP	590,116	$19.52M	0.02%	—	New position
2	TWO SIGMA INVESTMENTS, LP	TWO SIGMA INVESTMENTS, LP	366,099	$16.95M	0.03%	—	New position

COLLEGIUM PHARMACEUTICAL, INC

Price chart

Recent event timeline

Recent earnings

Research actions

Top news

Key stats

Date	Firm	Analyst	Action	Rating change	Price target	Report
2026. 03. 20.	HC Wainwright & Co.	—	Maintain	Buy → Buy	—	HC Wainwright & Co.: Buy
2026. 03. 19.	Needham	—	Maintain	Buy → Buy	—	Needham: Buy
2026. 02. 27.	Needham	—	Maintain	Buy → Buy	—	Needham: Buy
2026. 01. 09.	Barclays	—	Maintain	Overweight → Overweight	—	Barclays: Overweight
2026. 01. 09.	HC Wainwright & Co.	—	Maintain	Buy → Buy	—	HC Wainwright & Co.: Buy
2026. 01. 08.	Needham	—	Maintain	Buy → Buy	—	Needham: Buy